Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

177.11 +5.38 (+3.13%)
Streaming Delayed Price Updated: 10:38 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
70 71 Next >
ABBV: This Top Biotech Just Went On A Buying Spree
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel). 
Via Talk Markets
2 No-Brainer Dividend Stocks to Buy for the New Year
These companies have fantastic track records of maintaining and raising their payouts. 
Via The Motley Fool
3 Dividend Stars Every Investor Should Own to Survive a Market Crash
Prepare for the worst but hope for the best by buying dividend stocks for a market crash that can provide both growth and income. 
Via InvestorPlace
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
AbbVie Stock Moves With Rising Relative Strength, Still Room To Grow
AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
AbbVie Inc. (NYSE: ABBV) Records 52-Week High Wednesday Morning
Via Investor Brand Network
$1000 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Via Benzinga
AbbVie Inc Chart Analysis
Technical analysis of the stock chart for ABBV. 
Via Talk Markets
Breaking Down AbbVie: 7 Analysts Share Their Views
Via Benzinga
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
2 Genius Safe Stocks to Buy for 2024 and Beyond
These companies have considerable profits and tried-and-true dividends in common. 
Via The Motley Fool
7 Dividend Aristocrats That Will Pay You for Years to Come
If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024. 
Via InvestorPlace
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024
These stocks may help you win in 2024 -- no matter what the market does. 
Via The Motley Fool
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
Via Benzinga
S&P 500 Shatters Records: The Top-Performing Stocks In January 2024
2023 was a historical milestone for S&P 500 as it once again surpassed record highs, largely due to tech giants and artificial intelligence. Top gainers were NVIDIA, Meta Platforms, and AMD. 
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Pfizer, Autodesk, AbbVie And More: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named Health Care Select Sector SPDR Fund (NYSE: XLV) 
Via Benzinga
AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. 
Via Benzinga
2 Beaten-Down Stocks to Buy Hand Over Fist This Year
Don't give up on these stocks too soon. 
Via The Motley Fool
Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness
Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocular inflammation. 
Via Benzinga
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management named Crown Castle Inc. 
Via Benzinga
Better Growth Stock: Abbott vs. AbbVie
These healthcare giants also offer investors the promise of increasing passive income. 
Via The Motley Fool
Here's the Average Amount Investors Have in Stocks by Age 40 and Which Stocks I Recommend Today
Curious as to how your portfolio stacks up? Take a look. 
Via The Motley Fool
AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback. 
Via Benzinga
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
AbbVie Inc's (NYSE: ABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing... 
Via Benzinga
Exposures Product Safety
2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade
Strong advantages over the competition could allow these businesses to keep raising their dividend payouts for at least another 10 years. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Simple Tricks That Every Investor Should Use (but Most Don't)
Having a few tricks up your sleeve can increase your returns over time. 
Via The Motley Fool
Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE: O) and recommends staying with it. "It’s a very steady story," he noted. 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
70 71 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.